TREACE MEDICAL CONCEPTS ($NASDAQ:TMCI) reported total revenue of USD 42.0 million for the second quarter of FY2023 ending June 30 2023, which represented a 40.0% increase year-over-year from the same period in FY2022. Net income for the quarter improved from -17.2 million in the previous year to -12.3 million.
Analysis – TMCI Stock Fair Value
GoodWhale has conducted an in-depth analysis of the fundamentals of TREACE MEDICAL CONCEPTS, a medical diagnostics company. Through our proprietary Valuation Line, we have determined the intrinsic value of the company’s stock to be $29.8. This means that the current market price of $20.1 is undervalued by 32.5%, presenting a potential buying opportunity for savvy investors. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for TMCI. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for TMCI. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for TMCI. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for TMCI are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company has a strong product portfolio and a wide geographical presence. The company is facing stiff competition from its rivals Pace Medical Inc, Tenon Medical Inc, and EMvision Medical Devices Ltd.
EMvision Medical Devices Ltd is a medical device company that develops, manufactures, and markets non-invasive brain scanning devices. The company’s products include the EMvision Neuro-Monitor, which is used for the detection and monitoring of seizures, and the EMvision Glioma Scanner, which is used for the diagnosis and treatment of brain tumors. The company was founded in 2006 and is headquartered in Sydney, Australia.
TREACE MEDICAL CONCEPTS reported impressive financial results for the 2nd Quarter of FY2023, with total revenue reaching USD 42.0 million – a 40.0% increase from the same period in the previous year. Net income increased to USD -12.3 million, a significant improvement from the -17.2 million reported in the 2nd quarter of FY2022. Investors should take note of the strong revenue growth and the improved net income, which suggest that TREACE MEDICAL CONCEPTS is well-positioned for further success.